111 related articles for article (PubMed ID: 30595152)
1. Strategies to overcome therapeutic resistance in renal cell carcinoma.
Siska PJ; Beckermann KE; Rathmell WK; Haake SM
Urol Oncol; 2017 Mar; 35(3):102-110. PubMed ID: 28089416
[TBL] [Abstract][Full Text] [Related]
2. New treatment options for metastatic renal cell carcinoma with prior anti-angiogenesis therapy.
Zarrabi K; Fang C; Wu S
J Hematol Oncol; 2017 Feb; 10(1):38. PubMed ID: 28153029
[TBL] [Abstract][Full Text] [Related]
3. Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma.
Carlo MI; Voss MH; Motzer RJ
Nat Rev Urol; 2016 Jul; 13(7):420-31. PubMed ID: 27324121
[TBL] [Abstract][Full Text] [Related]
4. Adverse Event Management in Patients with
Chalmers A; Cannon L; Akerley W
Oncologist; 2019 Jul; 24(7):963-972. PubMed ID: 30598499
[TBL] [Abstract][Full Text] [Related]
5. Real-world management of patients with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer in the USA.
Li Y; Appius A; Pattipaka T; Feyereislova A; Cassidy A; Ganti AK
PLoS One; 2019; 14(1):e0209709. PubMed ID: 30608948
[TBL] [Abstract][Full Text] [Related]
6. Real-world benefit of nivolumab in a Canadian non-small-cell lung cancer cohort.
Juergens RA; Mariano C; Jolivet J; Finn N; Rothenstein J; Reaume MN; Faghih A; Labbé C; Owen S; Shepherd FA; Villeneuve J; Romeyer F; Pettersson F; Butts C
Curr Oncol; 2018 Dec; 25(6):384-392. PubMed ID: 30607113
[TBL] [Abstract][Full Text] [Related]
7. Genomic Fabric Remodeling in Metastatic Clear Cell Renal Cell Carcinoma (ccRCC): A New Paradigm and Proposal for a Personalized Gene Therapy Approach.
Iacobas DA; Mgbemena VE; Iacobas S; Menezes KM; Wang H; Saganti PB
Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33302383
[TBL] [Abstract][Full Text] [Related]
8. [Not Available].
Mery B; Jones S; Vallard A; Rowinski E; Guillot A; Magné N
Bull Cancer; 2018 Dec; 105 Suppl 3():S235-S241. PubMed ID: 30595152
[TBL] [Abstract][Full Text] [Related]
9. [Not Available].
Falkowski S
Bull Cancer; 2018 Dec; 105 Suppl 3():S255-S260. PubMed ID: 30595154
[TBL] [Abstract][Full Text] [Related]
10. Evolving role of novel targeted agents in renal cell carcinoma.
Hutson TE; Figlin RA
Oncology (Williston Park); 2007 Sep; 21(10):1175-80; discussion 1184, 1187, 1190. PubMed ID: 17926797
[TBL] [Abstract][Full Text] [Related]
11. Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors.
Turnbull JD; Cobert J; Jaffe T; Harrison MR; George DJ; Armstrong AJ
Clin Genitourin Cancer; 2013 Mar; 11(1):45-50. PubMed ID: 23041453
[TBL] [Abstract][Full Text] [Related]
12. Combination therapy in metastatic renal cell cancer.
Ravaud A; Gross-Goupil M; Bellmunt J
Semin Oncol; 2013 Aug; 40(4):472-81. PubMed ID: 23972711
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category.
Davis ID; Xie W; Pezaro C; Donskov F; Wells JC; Agarwal N; Srinivas S; Yuasa T; Beuselinck B; Wood LA; Ernst DS; Kanesvaran R; Knox JJ; Pantuck A; Saleem S; Alva A; Rini BI; Lee JL; Choueiri TK; Heng DYC
Eur Urol; 2017 Jun; 71(6):970-978. PubMed ID: 27771126
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
